奥地利全国注册研究:原发前列腺癌超低分割直线加速器放疗早期结果
该多中心前瞻性注册研究纳入169例低危和中危局限性前列腺癌患者,所有患者接受40 Gy分5次超低分割直线加速器SBRT。中位随访14个月,12个月时中位PSA从基线7.74 ng/mL降至0.63 ng/mL,第一年未观察到生化复发,≥3级泌尿生殖毒性<1%,未观察到≥3级胃肠道毒性。
要点
- 低中危前列腺癌40 Gy分5次超低分割SBRT耐受良好。
- 12个月中位PSA降至0.63 ng/mL,第一年无生化复发。
- ≥3级泌尿生殖毒性<1%,无≥3级胃肠道毒性。
核心结论
- 在这项全国真实世界队列中,5次超低分割放疗耐受良好,早期肿瘤学结局良好,严重毒性发生率低,与随机III期试验结果一致。
研究设计与样本
- 多中心、注册为基础的前瞻性研究,纳入低危和中危局限性前列腺癌患者,最终分析169例。
主要发现
- 中位随访14个月(IQR 7-24),NCCN风险分布为低危23.7%、有利中危48.5%、不利中危27.8%。
- 所有患者接受40 Gy分5次,61.5%隔日照射、38.5%连续工作日照射。
- 中位PSA从基线7.74 ng/mL降至12个月时0.63 ng/mL,第一年随访未观察到生化复发。
- 1-2级泌尿生殖毒性在治疗完成时达峰后下降,≥3级毒性<1%;胃肠道毒性全程低,未观察到≥3级胃肠道毒性。
临床怎么用
- 低中危局限性前列腺癌可考虑40 Gy分5次直线加速器SBRT,需关注泌尿生殖毒性并在治疗完成时达峰后随访。
局限性
- 中位随访仅14个月,早期结果不足以评估长期肿瘤学结局和晚期毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Ultrahypofractionated radiotherapy (UHFX) has emerged as an attractive alternative to normo- and moderately hypofractionated regimens for localized prostate cancer. However, its broader adoption remains limited by technical challenges and concerns regarding genitourinary toxicity. We established a nationwide Austrian registry of low and intermediate risk localized prostate cancer patients treated with linac-based stereotactic body radiation therapy (SBRT) to provide real-world data about UHFX treatment conventions, toxicity, oncologic outcomes, and patient-reported quality of life (QoL). METHODS: This is a multicenter, registry-based prospective study. Eligibility was restricted to patients with low- and intermediate-risk prostate cancer. Patient characteristics, toxicity (CTCAE v5.1), urinary function (IPSS), and QoL (EPIC-26) were prospectively reported in a web-based database. RESULTS: Between September 2022 and April 2026, 191 patients were enrolled, of whom 169 were included in the final analysis. Median follow-up was 14 months (IQR 7-24). NCCN risk distribution consisted of 23.7% low-risk, 48.5% favorable intermediate-risk, and 27.8% unfavorable intermediate-risk disease. All patients received 40 Gy in five fractions. Treatment was delivered on alternating weekdays in 61.5% and on consecutive weekdays in 38.5% of patients. Median PSA declined from 7.74 ng/mL at baseline to 0.63 ng/mL at 12 months. No biochemical recurrence was observed during the first year of follow-up. Grade 1-2 genitourinary toxicity peaked at treatment completion and declined thereafter, while grade ≥ 3 toxicity remained uncommon (<1%). Gastrointestinal toxicity remained low throughout follow-up, with no grade ≥ 3 gastrointestinal toxicity observed. CONCLUSION: In this nationwide real-world cohort, UHFX delivered in five fractions was well tolerated and showed favorable early oncological outcomes with low rates of severe toxicity across academic and non-academic institutions, consistent with results from randomized phase III trials.
引用
- Annon-Eberharter N, Berchtold J, Ginestet A, et al. Ultrahypofractionated linac-based radiotherapy of primary prostate cancer - early results of an Austrian nationwide registry study. Clin Transl Radiat Oncol. 2026. PMID: 42621857. doi:10.1016/j.ctro.2026.101242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。